Welcome to our dedicated page for Solventum news (Ticker: SOLV), a resource for investors and traders seeking the latest updates and insights on Solventum stock.
Solventum Corporation (NYSE: SOLV) generates a steady flow of news that reflects its role in the medical instruments and supplies sector and its focus on MedSurg, Dental Solutions and Health Information Systems. News about Solventum often highlights developments in advanced wound care, portfolio changes, capital allocation decisions and strategic initiatives intended to support long-term growth.
Recent announcements include agreements and completion of the acquisition of Acera Surgical, a bioscience company focused on fully engineered materials for regenerative wound care. These updates describe how Solventum is expanding its MedSurg portfolio into the synthetic tissue matrices technology space within acute care settings. Other news covers clinical and scientific developments, such as international consensus recommendations on the use of closed incision negative pressure therapy with reticulated open cell foam dressings, which relate directly to Solventum Prevena Therapy and its application across surgical specialties.
Investors and healthcare professionals following SOLV news will also see coverage of financial results, including quarterly earnings releases and guidance updates, as well as information about Solventum’s “Transform for the Future” initiative to reshape its cost structure and support innovation. Capital markets and balance sheet actions, such as cash tender offers for outstanding notes, the sale of the purification and filtration business to Thermo Fisher Scientific Inc., and the authorization of a share repurchase program, are reported through both press releases and SEC filings.
Additional news items may feature recognition of operational capabilities, such as the Diamond Level Resiliency Badge from the Healthcare Industry Resilience Collaborative for supply chain strength in the MedSurg segment, and participation in healthcare investor conferences. By reviewing the SOLV news feed on a regular basis, readers can track how Solventum’s strategic decisions, clinical evidence, portfolio moves and financial performance are communicated to the market over time.
Solventum (NYSE: SOLV) has announced it will release its first quarter fiscal 2025 financial results on Thursday, May 8, 2025, following the close of U.S. financial markets. The company will host a webcast at 3:30 p.m. CST / 4:30 p.m. EST to discuss the quarterly results and business updates.
The earnings webcast will be accessible through the company's investor relations website at investors.solventum.com. Participants can join via U.S. dial-in at +1 (800) 715-9871 or international dial-in at +1 (646) 307-1963 using Conference ID 6342275. Following the event, the webcast replay, earnings release, presentation slides, and supplemental financial information will be made available on Solventum's investor relations website.
Solventum (NYSE: SOLV) has announced a strategic partnership with SprintRay to revolutionize digital dentistry through same-day permanent restorations. The collaboration combines Solventum's expertise in dental composites and restorative materials with SprintRay's chairside 3D printing technology.
The R&D and commercialization agreement aims to develop the first permanent chairside 3D printed crown, along with inlays and onlays. This partnership promises to reduce patient visits, improve practice efficiency, and lower treatment costs while maintaining the quality expected from traditional laboratory-fabricated procedures.
The announcement aligns with Solventum's growth strategy and follows their recent launch of four new products in 2024, including 3D printed aligner attachments, fluoride treatment, multi-layer copolymer aligners, and universal restorative solutions. More details will be shared at the International Dental Show 2025 in Cologne, Germany.
Solventum (NYSE: SOLV) hosted its 2025 Investor Day to present its strategic priorities and long-range plan through 2028. CEO Bryan Hanson outlined the company's transformation following the sale of its Purification & Filtration business, focusing on Medical Surgical, Dental Solutions, and Health Information Systems segments.
The company announced key 2028 targets including:
- Organic sales growth of 4-5%
- Operating margins expansion to 23-25%
- EPS CAGR of 10% over 3 years
- Free cash flow conversion above 80%
Solventum's three-phase transformation plan includes:
- Stabilizing the business through culture and talent enhancement
- Enhancing strategic focus in high-potential markets
- Portfolio optimization through organic and inorganic growth opportunities
Solventum (NYSE: SOLV) has launched the Attest™ eBowie-Dick Test System, an innovative electronic sterilization testing solution that provides instant digital results and automated documentation. The system delivers definitive pass/fail results in under five seconds and integrates with hospital instrument tracking systems.
The new technology replaces traditional color-changing ink indicators used in steam dynamic-air removal sterilizers, reducing paper waste by 94% compared to conventional Bowie-Dick Test Packs. The system is now available in the United States through authorized distributors, with global rollout planned throughout 2025.
According to Chris Barry, executive vice president and group president of Medical Surgical at Solventum, the eBowie-Dick System revolutionizes sterilization testing by reducing processing times, eliminating result variability, and providing advanced analytics capabilities.
Solventum (NYSE: SOLV) reported Q4 2024 financial results with reported sales increasing 1.9% to $2.074 billion and organic sales growth of 2.3%. The company posted GAAP diluted EPS of $0.17 and adjusted EPS of $1.41, while generating $219 million in cash from operations and $92 million in free cash flow.
Growth was driven primarily by the MedSurg and Dental Solutions segments, though operating margins declined due to lower gross margins and increased operating expenses related to public company stand-up costs.
For 2025 guidance, Solventum projects:
- Organic sales growth of 1.0% to 2.0% (+1.5% to 2.5% excluding SKU Exit impact)
- Adjusted EPS of $5.45 to $5.65
- Free cash flow of $450M to $550M
Solventum (NYSE: SOLV) has announced plans to host an important Investor Day event on Thursday, March 20, 2025, in New York City. The event, scheduled to begin at 1:00 p.m. Eastern Standard Time, will provide insights into the company's long-term growth strategy.
The presentation will be accessible both in-person and through a virtual webcast format. Interested participants can find registration details and additional information at the company's investor relations website: https://investors.solventum.com. A replay of the webcast will be made available shortly after the conclusion of the live event.
Solventum (NYSE: SOLV) has announced the sale of its Purification & Filtration business to Thermo Fisher Scientific Inc. (NYSE: TMO) for $4.1 billion. This strategic divestiture is part of phase three of Solventum's transformation plan, aimed at sharpening focus on strategic growth areas and delivering long-term shareholder value.
The transaction is expected to be completed by the end of 2025, subject to regulatory approval and customary closing conditions. Solventum anticipates $3.4 billion in net proceeds, which will be primarily used to pay down debt, strengthening its balance sheet and reducing leverage.
According to CEO Bryan Hanson, this move will enhance Solventum's strategic focus and key metrics while enabling investment in innovation, programs, and talent. The company will discuss the transaction during its upcoming Q4 and full-year 2024 earnings call on February 27, 2025, with an Investor Day scheduled for March 20, 2025.
Thermo Fisher Scientific (NYSE: TMO) has announced a definitive agreement to acquire Solventum's Purification & Filtration business for approximately $4.1 billion in cash. The Solventum business, which generated approximately $1 billion of revenue in 2024, is a leading provider of purification and filtration technologies used in biologics production and other applications.
This acquisition is highly complementary to Thermo Fisher's bioproduction business, expanding its capabilities in biologics development and manufacturing. The transaction is expected to be completed by the end of 2025, subject to regulatory approvals. Once closed, Solventum's business will become part of Thermo Fisher's Life Sciences Solutions segment.
The acquisition is expected to generate mid- to high-single digit organic growth and will be dilutive to adjusted EPS by $0.06 in the first year, but accretive by $0.28 excluding financing costs. Thermo Fisher expects to realize approximately $125 million of adjusted operating income from synergies by year five.
Solventum (NYSE: SOLV) announced that its AI-powered radiology speech reporting solution, Fluency for Imaging, has been ranked #1 in the 2025 Best in KLAS Awards for the fifth time. The solution helps radiologists improve efficiency and reduce burnout by streamlining the reporting process through faster, more accurate documentation.
Dr. Charles Q. Li from Allegheny Health Network praised the system's exceptional voice recognition accuracy and reliability, noting its decade-long use at their facility. The KLAS recognition is based on customer feedback collected through confidential interviews and product evaluations over a one-year period, evaluating solutions across six key pillars: value, product, loyalty, relationship, operations, and culture.